We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While many voters are upset at the high cost of prescription drugs, pharmaceutical issues are not likely to determine the outcome of the presidential election, according to some political observers.
Thousands of lawsuits are pending against Merck as a result of the firm’s decision to withdrawal its popular and widely prescribed arthritis medicine, Vioxx, from the market after clinical studies revealed an increased risk of heart attack and stroke in patients taking the drug.
The governors of Wisconsin and Illinois have launched the first state-sponsored prescription drug importation program to allow millions of Americans to buy drugs not only from Canada, but the UK and Ireland as well.
The world’s largest drugmaker has launched an ambitious prescription drug plan that allows tens of millions of uninsured patients in the U.S. to purchase its medicines at significant discounts.
Medicare drug-plan sponsors may not be required to cover biologics that treat rare diseases and disorders, according to the Biotechnology Industry Organization (BIO), which urged federal regulators to ensure drug plans include the unique and often costly therapies.
In defiance of federal law, the governors of Wisconsin and Illinois have launched the first state-sponsored prescription drug importation program to allow millions of Americans to buy drugs not only from Canada, but the UK and Ireland as well.
A new business division created by Johnson & Johnson (J&J) may be the brand manufacturer’s first step toward competing in the generic drug market, industry observers say.
Despite what the pharmaceutical industry says, drugmakers spend far less on R&D compared to what they spend on marketing, according to a prominent industry critic who suggests that U.S. big pharma should be subject to a national pricing scheme similar to one in Canada.
More than 100 lawsuits have been filed since Merck announced last week that it was withdrawing its popular and widely prescribed arthritis medicine Vioxx from the market after clinical studies revealed an increased risk of heart attack and stroke in patients taking the drug.